Ocular Therapeutix to Showcase Axpaxli Data at Key Retina Conferences
Event summary
- Ocular Therapeutix will present Phase 3 SOL-1 trial data for Axpaxli at multiple retina conferences in October 2026
- CEO Pravin Dugel to participate in Chardan Healthcare Conference fireside chat on October 20, 2026
- Key presentations include Eyecelerator @ AAO and Innovate Retina on October 8, 2026
- American Academy of Ophthalmology events feature multiple Axpaxli-related presentations October 9-12, 2026
The big picture
Ocular Therapeutix's conference presence highlights the critical phase of its Axpaxli development program, with Phase 3 data representing a potential inflection point for the wet AMD treatment market. The company's ELUTYX hydrogel technology platform positions it as a key player in sustained-release retinal therapies, competing with established players in the $8 billion wet AMD market.
What we're watching
- Clinical Validation
- Whether Phase 3 SOL-1 trial results will demonstrate superior efficacy for Axpaxli in wet AMD
- Market Positioning
- How Ocular Therapeutix positions Axpaxli against existing wet AMD treatments
- Regulatory Pathway
- The timeline for potential FDA submission based on SOL-1 trial outcomes
Related topics